Condition: Pancreatic Acinar Cell Carcinoma · Pancreatic Adenosquamous Carcinoma · Pancreatic Squamous Cell Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Suspended |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Suspended |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Suspended |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Suspended |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Suspended |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Suspended |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | Suspended |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | Active Not Recruiting |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | Suspended |
+ 442 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04858334